← Compound index
RESEARCH FAMILY / GEPON

Gepon & ezrin-derived peptidesГепон

A synthetic 14-amino-acid peptide based on the human protein ezrin, studied in infection and inflammation research.

Immune Function
Source linked

What the studies found

Comparison in people · 2004

Gepon and Immunomax in 126 people with acute surgical wound infections

Complete wound healing by secondary intention
18.4 ± 1.3 vs 20.5 ± 1.4 daysp<0.05 as reported
Clearance of purulent necrotic material
9.9 ± 1.2 vs 12.5 ± 1.5 days
Day-three wound area as percentage of baseline
93.5 ± 2.4% vs 96.5 ± 2.1%The paper reports significance against baseline.

In wounds healing by secondary intention, healing averaged 18.4 vs 20.5 days with the combination and comparison care, respectively.

Study notes · methods, sources and limitations

Participants or model 126 surgical patients with acute purulent soft-tissue infection. Combination group: 65. Standard-care comparison: 61.

Design Single-center comparative series. Both groups received surgery and wound care. Outcomes included wound planimetry and time to clearing and healing.

Important limitations

  • Concurrent treatments differed. The effect of Gepon alone cannot be estimated from this comparison. The healing figure concerns the secondary-intention subset. The two journals report the same 126 patients and regimen.

Russian Medical Journal. 2004;(24). Also published in Pharmateca. · Publication record

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2005

Gepon versus valacyclovir in recurrent genital herpes

Epithelialization and lesion healing
Reported faster with GeponNumerical effect unavailable in the abstract.
Length of remission
No extension with GeponThe abstract describes an extension with valacyclovir.

The authors reported faster lesion healing and less severe recurrence symptoms with Gepon. They reported no extension of remission with Gepon.

Study notes · methods, sources and limitations

Participants or model 42 women with severe recurrent genital herpes. Arm sizes were not stated in the accessible original abstract.

Design Clinical treatment comparison during recurrence, based on the original publisher abstract.

Important limitations

  • The full tables are needed for group sizes, dosing and recurrence estimates. The 2004 citation may describe the same study.

Pharmateka. 2005;2(98). · Publication record

Original source or citation ↗

Study results and tables ↗

Observational study · 2005

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

Clinical and endoscopic amelioration
83.3%Within the treated cohort; no untreated response rate supplied

In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.

Study notes · methods, sources and limitations

Participants or model 36 patients with resistant distal ulcerative colitis

Design 36 patients with resistant distal UC; adjunctive immunomodulation.

Participants
36

Important limitations

  • No concurrent comparator is described; the reported response proportion is not an effect versus placebo or standard care. Full methods, reporting completeness and independent replication remain to be appraised.
  • The percentage is an uncontrolled response proportion, not a placebo-adjusted remission rate. Long-term relapse and adverse-event rates are not quantified.

Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847 · Original journal report

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Gepon & ezrin-derived peptides

Names in this research collection

HEP1 · HEP-1 · TEKKRRETVEREKE · HP-V2 · TEKKR · RETVEREKE

Identity / background source ↗

Research background

An ezrin-related peptide family with a patent identity trail, an uncontrolled human ulcerative-colitis report and preclinical experiments. Related fragments are separate research objects.

Compound class
Peptide research family
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

36 patients with resistant distal ulcerative colitis

Study methods

Study records describe the tested models, comparators and reported outcomes.

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
Gepon / HEP1TEKKRRETVEREKE

The uncontrolled 36-patient report describes an 83.3% response proportion; this cannot establish a treatment effect without a comparator. Mouse colitis and fibroblast experiments are separate evidence.

Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 ↗

[Use of the Gepon immunomodulator for ulcerative colitis treatment]. ↗

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes. ↗

Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts. ↗

HP-V2GEKKRRETVEREGG

Modified peptide; not equivalent to the parent.

Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 ↗

Shorter fragmentsTEKKR / RETVEREKE

Patent-discussed fragments; separate identity and evidence required.

Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 ↗

Interpretation and open questions

Human and preclinical publications now supplement the patent identity trail. Results do not transfer to HP-V2 or shorter fragments; registration and clinical effectiveness require separate verification.

Explore the Russian peptide research map ↗

What remains unclear

The 36-patient ulcerative-colitis study reports response without a control group. Comparator and longer follow-up data remain limited.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2017 · US9682140B2 · Ezrin-derived peptides and pharmaceutical compositions — US9682140B2Molecule · 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control

Reported findings

The modified peptide increased MAPK/ERK phosphorylation in cell cultures.

Phospho-ERK1
0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control1 hourNormalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02
Phospho-ERK2
1.30 ± 0.05 versus 0.40 ± 0.01 negative control1 hourPositive TGF-β1 control 1.90 ± 0.10
All reported results, comparisons and limitations →

Molecule. Ezrin-derived peptide and composition claims; the claimed modified sequences are not automatically identical to the parent Gepon peptide or every marketed formulation.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US9682140B2 ↗ · 2017-06-20
Earliest priority / filing
2015-06-01 / 2016-06-01
Original applicant / assignee
Nearmedic International Ltd
Indexed status
Active · checked 2026-11-06
Patent family
56117690 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Ezrin-derived peptides and pharmaceutical compositions thereof

Inventors: Rupert Holms; Ravshan Ataullakhanov; Rustam Ataullakhanov; Khachik Sayadyan.

US9682140B2 · EP3191504B1 · JP6721419B2 · KR101842978B1 · CN106188267B · AU2016203656B2 · CA2931875C · CY1120501T1 · DK3191504T3 · ES2660894T3 · GB2546439B · HRP20180560T1 · HUE038737T2 · LT3191504T · MA39421A · MD3191504T2 · ME03033B · MX377333B · PL3191504T3 · PT3191504T · RS57067B1 · SG10201604401UA · SI3191504T1 · SMT201800190T1 · WO2016193285A1 · ZA201603723B

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Comparison in people · 2004

Gepon and Immunomax in 126 people with acute surgical wound infections

In wounds healing by secondary intention, healing averaged 18.4 vs 20.5 days with the combination and comparison care, respectively.

Complete wound healing by secondary intention · 18.4 ± 1.3 vs 20.5 ± 1.4 days · p<0.05 as reported

Study notes and original source
2004Human comparative studyFull text available

Gepon and Immunomax in 126 people with acute surgical wound infections

A. P. Chadaev, A. M. Nurpisov, A. V. Pichugin, R. I. Ataullakhanov · Russian Medical Journal. 2004;(24). Also published in Pharmateca.

In wounds healing by secondary intention, healing averaged 18.4 vs 20.5 days with the combination and comparison care, respectively.

Results and tables

Reported findings and study design

Single-center comparative series. Both groups received surgery and wound care. Outcomes included wound planimetry and time to clearing and healing.

Population or model 126 surgical patients with acute purulent soft-tissue infection. Combination group: 65. Standard-care comparison: 61.

Dose, route and schedule

Immunomax 200 units intramuscularly on alternate days for three injections, then topical 0.004% Gepon dressings as the wound entered the second phase. Comparison care included 10% methyluracil in that phase.

Protocol source ↗ · Original Russian Medical Journal article and matching Pharmateca report.

Results · Original Russian Medical Journal article and matching Pharmateca report.
MeasureResultComparison, timing and statistics
Complete wound healing by secondary intention18.4 ± 1.3 vs 20.5 ± 1.4 daysp<0.05 as reported
Clearance of purulent necrotic material9.9 ± 1.2 vs 12.5 ± 1.5 days
Day-three wound area as percentage of baseline93.5 ± 2.4% vs 96.5 ± 2.1%The paper reports significance against baseline.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
126 surgical patients with acute purulent soft-tissue infection. Combination group: 65. Standard-care comparison: 61.
Source reviewed
Original Russian Medical Journal article and matching Pharmateca report.
Study limitations
  • Concurrent treatments differed. The effect of Gepon alone cannot be estimated from this comparison. The healing figure concerns the secondary-intention subset.
  • The two journals report the same 126 patients and regimen.

Reviewed 2026-11-15.

Read the source ↗

Comparison in people · 2005

Gepon versus valacyclovir in recurrent genital herpes

The authors reported faster lesion healing and less severe recurrence symptoms with Gepon. They reported no extension of remission with Gepon.

Study notes and original source
2005Human comparative studyRussian-language source

Gepon versus valacyclovir in recurrent genital herpes

L. A. Marchenko, I. A. Lushkova, A. V. Shurshalina · Pharmateka. 2005;2(98).

The authors reported faster lesion healing and less severe recurrence symptoms with Gepon. They reported no extension of remission with Gepon.

Results and tables

Reported findings and study design

Clinical treatment comparison during recurrence, based on the original publisher abstract.

Population or model 42 women with severe recurrent genital herpes. Arm sizes were not stated in the accessible original abstract.

Protocol information

Oral and topical Gepon during a recurrence versus valacyclovir. Dose, schedule and comparator allocation are unavailable in the publisher abstract.

Protocol source ↗ · Original publisher abstract. A 2004 citation lists matching authors and topic.

Results · Original publisher abstract. A 2004 citation lists matching authors and topic.
MeasureResultComparison, timing and statistics
Epithelialization and lesion healingReported faster with GeponNumerical effect unavailable in the abstract.
Length of remissionNo extension with GeponThe abstract describes an extension with valacyclovir.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
42 women with severe recurrent genital herpes. Arm sizes were not stated in the accessible original abstract.
Source reviewed
Original publisher abstract. A 2004 citation lists matching authors and topic.
Study limitations
  • The full tables are needed for group sizes, dosing and recurrence estimates. The 2004 citation may describe the same study.

Reviewed 2026-11-14.

Read the source ↗

Observational study · 2005

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.

Study notes and original source
2005Uncontrolled human reportEnglish abstract

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

· Original journal report

Malakhova NS, Pichugin AV, Khalif IL, Ataullakhanov RI · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 15991847

In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.

Results and tables

Reported findings and study design

In a 36-person uncontrolled report of resistant distal ulcerative colitis, 83.3% had clinical and endoscopic improvement after Gepon.

36 patients with resistant distal UC; adjunctive immunomodulation.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Clinical and endoscopic amelioration83.3%Within the treated cohort; no untreated response rate supplied
Participants36

The percentage is an uncontrolled response proportion, not a placebo-adjusted remission rate. Long-term relapse and adverse-event rates are not quantified.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
36 patients with resistant distal ulcerative colitis
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • No concurrent comparator is described; the reported response proportion is not an effect versus placebo or standard care.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 2020

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes.

Gepon reduced experimental colitis manifestations, inflammatory-cell infiltration and selected inflammatory gene signals.

Study notes and original source
2020Animal / experimentalEnglish abstract

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes.

· Original journal report

Chulkina MM, Pichugin AV, Ataullakhanov RI · Peptides · PMID 32621844

Gepon reduced experimental colitis manifestations, inflammatory-cell infiltration and selected inflammatory gene signals.

Population / setting
Mice with dextran-sodium-sulphate-induced colitis
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • A chemically induced mouse model does not establish benefit or safety in human ulcerative colitis.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗

Lab research · 2017

Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.

The defined TEKKRRETVEREKE peptide promoted differentiation-related changes through ERK1/2 signaling without SMAD activation.

Study notes and original source
2017In vitroEnglish abstract

Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.

· Original journal report

Chulkina M, Negmadjanov U, Lebedeva E, Pichugin A, Mazurov D, Ataullakhanov R, Holmuhamedov E · European journal of pharmacology · PMID 28668507

The defined TEKKRRETVEREKE peptide promoted differentiation-related changes through ERK1/2 signaling without SMAD activation.

Population / setting
NIH/3T3 mouse fibroblasts, including CD44-knockout cells
Source reviewed
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
  • Cell signaling does not quantify wound healing in patients.
  • Full methods, reporting completeness and independent replication remain to be appraised.

Reviewed 2026-10-05.

Read the source ↗

Experiment described in a patent · 2017

Ezrin-derived peptides and pharmaceutical compositions — US9682140B2

The granted claim class defines modified ezrin-derived peptides, including GEKKRRETVEREGG. A dependent composition also includes the parent Gepon sequence TEKKRRETVEREKE. Modified peptides and mixtures must not inherit Gepon clinical outcomes.

Phospho-ERK1 · 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control · Normalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01

Study notes and original source
2017Patent / reported experimentsFull text available

Ezrin-derived peptides and pharmaceutical compositions — US9682140B2

· Primary source linked above

The granted claim class defines modified ezrin-derived peptides, including GEKKRRETVEREGG. A dependent composition also includes the parent Gepon sequence TEKKRRETVEREKE. Modified peptides and mixtures must not inherit Gepon clinical outcomes.

Results and tables

Reported patent results

Reported findings

The modified peptide increased MAPK/ERK phosphorylation in cell cultures.

Fibroblast signaling experiments with modified ezrin-derived HP-V2; a different sequence from parent Gepon.

Population or model Ezrin-related patent chemistry and experimental examples

Results · Final fibroblast MAPK/ERK experiment; modified-peptide identity explicitly retained.
MeasureResultComparison, timing and statistics
Phospho-ERK10.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative controlNormalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01
Phospho-ERK21.30 ± 0.05 versus 0.40 ± 0.01 negative controlPositive TGF-β1 control 1.90 ± 0.10 · 1 hour · p<0.01

A fibroblast pathway response does not prove tissue repair or clinical efficacy. Values belong to HP-V2, not automatically Gepon, related fragments or every mixture.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Ezrin-related patent chemistry and experimental examples
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Modified sequences and mixtures must not inherit Gepon outcomes.
  • Clinical evidence appraisal remains pending.

Reviewed 2026-11-06.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗